NORGINES PARTNER TAKEDA RUSSIA-CIS LAUNCHES MOVIPREP IN RUSSIA

Back to media releases
Next media release
15 July 2016

CORPORATE PRESS RELEASE

 

NORGINE’S PARTNER TAKEDA RUSSIA-CIS LAUNCHES MOVIPREP® IN RUSSIA

 

LONDON. 15 July 2016, 07:00 AM BST. Norgine B.V. today announced that its partner Takeda Russia–CIS has launched MOVIPREP® in Russia. MOVIPREP® is indicated for bowel preparation prior to any procedure (endoscopic, radiologic, surgical or other procedures) which require a clean bowel.

 

MOVIPREP® is already available through this partnership in Ukraine, Kazakhstan, Mongolia and Armenia.

 

In 2011, Norgine out-licensed the rights for MOVIPREP® in Russia/CIS to Nycomed, which was subsequently acquired by Takeda.

 

Paul Pay, Chief Business Development Officer at Norgine said: “This new launch in a major market reinforces Norgine’s strategy to continue to launch MOVIPREP® through partners to ensure that the product is available in countries where Norgine does not have a direct presence.”

 

Russia ranks third in the worldwide bowel preparation market for procedures.[1]

 

MOVIPREP® was originally developed by Norgine. MOVIPREP® is currently available in Europe and Australia through Norgine’s own infrastructure and in Central Eastern Europe, the US, India, Japan, MENA and Canada via partners.

 

 

 

 

 

Notes to Editors:

About Norgine

Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2015, Norgine’s total revenue was EUR 320 million and the company employs over 1,000 people.

 

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients.  Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com

 

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

 

 

Norgine Media Contacts:

Isabelle Jouin, T: +44 (0)1895 453643

Charlotte Andrews, T: +44 (0)1895 453607

Follow us @norgine

 

 
GL/MPR/0716/0079

 


[1] Norgine Data on File.